Search
Prussian blue
go.drugbank.com/drugs/DB06783ApprovedPrussian blue is described as a deep blue pigment that is produced when the oxidation of ferrous ferrocyanide salts occurs. … Prussian blue is included in the World Health Organization Model List of Essential Medicines as a specific antidote used in poisonings to provide symptomatic and supportive treatment.
Categories: Compounds used in a research, industrial, or household settingEpithelial sodium channel subunit delta
go.drugbank.com/bio_entities/BE0000495TargetHumansPotential alternative pore-forming subunit of the epithelial sodium channel (ENaC), capable of replacing the alpha/SCNN1A subunit, creating a more active channel with distinct properties (PubMed:16423824, PubMed:19520916, PubMed:22505667...
Synonyms: Delta-NaCHRocuronium
go.drugbank.com/drugs/DB00728ApprovedInvestigational[Sugammadex] is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium. … It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma.
Products: BROMURO DE ROCURONIO 50 MG/5 ML SOLUCION INYECTABLE, BROMURO DE ROCURONIO 50 MG / 5 ML SOLUCIÓN INYECTABLEApomorphine
go.drugbank.com/drugs/DB00714ApprovedInvestigationalApomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884. … [A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.
Synonyms: (R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol, (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diolCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesRimexolone
go.drugbank.com/drugs/DB00896ApprovedWithdrawnRimexolone is a 1% eye drop solution is a glucocorticoid steroid. It is used to treat inflammation in the eye. It is marketed as Vexol.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersProducts: VEXOL 5 ML OFTALMIK SOLUSYON, Vexol Ophthalmic Suspension - 1%Talimogene laherparepvec
go.drugbank.com/drugs/DB13896ApprovedInvestigationalIt was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221]. … Alternatively, although talimogene laherparepvec also enters healthy cells, it is not designed to multiply inside them [L2221].
Synonyms: T Vec, T-VecRevefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigationalRevefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA). … The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesLomitapide
go.drugbank.com/drugs/DB08827Approved[A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446] … apo B-containing lipoproteins in the liver and intestines.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A InhibitorsSynonyms: 9H-FLUORENE-9-CARBOXAMIDE, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-1-PIPERIDINYL)BUTYL)-, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)BIPHENYL-2-YL)CARBONYL)AMINO)PIPERIDIN-1-YL)BUTYL)-9H-FLUORENE-9-CARBOXAMIDENonacog beta pegol
go.drugbank.com/drugs/DB13933ApprovedInvestigationalOnce activated, the activation molecule with PEG is cleaved to leave the activated factor IX (Factor IXa). … [A31496] Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the FDA on May 31, 2017,[L1098] followed by the European Commission approval on June 2, 2017.
Categories: Compounds used in a research, industrial, or household settingProducts: REFİXİA 500 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİNTOZ VE ÇÖZÜCÜ , 1 ADET FLAKON + 1 ADET ÇÖZÜCÜ İÇEREN KULLANIMA HAZIR ENJEKTÖR, REFİXİA 1000 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİNTOZ VE ÇÖZÜCÜ , 1 ADET FLAKON + 1 ADET ÇÖZÜCÜ İÇEREN KULLANIMA HAZIR ENJEKTÖRTeprotumumab
go.drugbank.com/drugs/DB06343ApprovedInvestigationalTeprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. … multiple invasive surgeries - teprotumumab is the first drug ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease.
Categories: Insulin-like Growth Factor-1 Receptor InhibitorSynonyms: Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human monoclonal heavy chain), disulfide with human monoclonal light chain, dimer